A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy

BJU International

Volumn 109, Issue 8, 2012, Pages 1177-1182

  Abdollah, Firas ^a,b   Schmitges, Jan ^a,c   Sun, Maxine ^a   Shariat, Shahrokh F ^d   Briganti, Alberto ^b   Abdo, Al'a ^a   Tian, Zhe ^a   Perrotte, Paul ^a   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Lymph node excision statistics and numerical data; Lymphatic metastasis diagnosis; Male; Pelvis; Prostatic neoplasm pathology; SEER program

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; PELVIS LYMPHADENECTOMY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; TREATMENT INDICATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEER PROGRAM; SURVIVAL RATE;

EID: 84860422773     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10518.x     Document Type: Article

References (21)

1. Briganti A, Blute ML, Eastham JH et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251-65
2. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
3. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-54 (Pubitemid 36188105)
4. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68: 121-5 (Pubitemid 44037727)
5. Masterson TA, Bianco FJ, Vickers AJ et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175: 1320-4
6. Briganti A, Chun FK, Salonia A et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-13 (Pubitemid 44486500)
7. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145-7 (Pubitemid 35461573)
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
9. Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31 (Pubitemid 46726449)
10. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology 2007; 70: 931-5 (Pubitemid 350192614)
11. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458-63 (Pubitemid 35292173)
12. Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-803 (Pubitemid 37254931)
13. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2008/. Based on November 2010 SEER data submission, posted to the SEER website, 2011
14. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999; 8: 1117-21 (Pubitemid 30004912)
15. Harlan LC, Hankey BF. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003; 21: 2232-3 (Pubitemid 46621856)
16. Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683-93 (Pubitemid 44917546)
17. Yu JB, Makarov DV, Sharma R, Peschel RE, Partin AW, Gross CP. Validation of the partin nomogram for prostate cancer in a national sample. J Urol 2010; 183: 105-11
18. Karakiewicz PI, Bhojani N, Capitanio U et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 2008; 180: 898-902
19. Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-53 (Pubitemid 41535365)
20. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169: 946-50 (Pubitemid 36188131)
21. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112: 2401-8